Fig 1: Cancer‐associated fibroblasts (CAFs) increased ZNF384 m6A modification by enhancing methyltransferase‐like 3 (METTL3) H3K18 lactylation. CAFs were isolated from non‐small cell lung cancer tissues. (A) Representative immunofluorescence images of α‐SMA and FSP1 in CAFs. (B) Lactate production was measured by a lactic acid test kit. A549 and H1299 cells treated with conditioned medium (CM) from CAFs and NFs. (C and D) RT‐qPCR and Western blot were performed to determine ZNF384 and METTL3 expression. (E) Methylated RNA immunoprecipitation (MeRIP) assay was applied to detect the m6A levels for ZNF384. sh‐NC or sh‐METTL3 was transfected into A549 and H1299 cells for 24 h (F) METTL3 expression was determined by RT‐qPCR. A549 and H1299 cells were treated with CM from CAFs or NFs and were transfected with sh‐METTL3 or sh‐NC. (G and H) RT‐qPCR and Western blot were conducted to evaluate ZNF384 expression. (I) MeRIP assay was applied to detect m6A modification levels of ZNF384. A549 and H1299 cells were co‐cultured with CAFs or NFs for 24 h. *p < 0.05, **p < 0.01, ***p < 0.001.
Supplier Page from Abcam for Anti-Ferroptosis suppressor protein 1 antibody